SCHEMBL14413302

SCHEMBL14413302

O=S(=O)(O)c1ccc(-c2ccc(/N=N/c3c(O)ccc4cc(S(=O)(=O)O)ccc34)cc2)cc1

nearest known ligand 0.79

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP2C9 P11712 3/20 0.79
▸ CYP1A2 P05177 3/20 0.79
▸ THRB P10828 2/20 0.68
▸ HIF1A Q16665 3/20 0.61
▸ CYP2C19 P33261 2/20 0.61
▸ HSD17B10 Q99714 2/20 0.61
▸ TSHR P16473 1/20 0.61
▸ PTPRA P18433 1/20 0.61
▸ PTPRB P23467 1/20 0.61
▸ RAPGEF4 Q8WZA2 1/20 0.61
▸ KMT2A Q03164 3/20 0.58
▸ MAPT P10636 2/20 0.58
▸ TDP1 Q9NUW8 2/20 0.58
▸ GAA P10253 1/20 0.58
▸ MAPK1 P28482 1/20 0.58
▸ ENPP2 Q13822 4/20 0.57
▸ MEN1 O00255 2/20 0.55
▸ SUMO2 P61956 1/20 0.51
▸ SUMO1 P63165 1/20 0.51
▸ SENP7 Q9BQF6 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL112146 0.96 CYP1A2 (0.85) CYP2C9CYP1A2THRBHIF1ACYP2C19
SCHEMBL14418343 0.96 CYP1A2 (0.85) CYP2C9CYP1A2THRBHIF1ACYP2C19
SCHEMBL30940027 0.96 CYP1A2 (0.85) CYP2C9CYP1A2THRBHIF1ACYP2C19
SCHEMBL142459 0.96 CYP1A2 (0.85) CYP2C9CYP1A2THRBHIF1ACYP2C19
SCHEMBL628908 0.96 CYP1A2 (0.85) CYP2C9CYP1A2THRBHIF1ACYP2C19
SCHEMBL142457 0.95 CYP1A2 (0.83) CYP2C9CYP1A2THRBHIF1ACYP2C19
SCHEMBL30486026 0.95 CYP1A2 (0.83) CYP2C9CYP1A2THRBHIF1ACYP2C19
SCHEMBL4808250 0.95 CYP1A2 (0.83) CYP2C9CYP1A2THRBHIF1ACYP2C19
SCHEMBL28291310 0.95 CYP1A2 (0.83) CYP2C9CYP1A2THRBHIF1ACYP2C19
SCHEMBL5321833 0.91 CYP2C9 (0.81) CYP2C9CYP1A2THRBHIF1ACYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7264932-B2 Nuclease inhibitor cocktail APPLERA CORPORATION (US) 2007-09-04 — — US disclosed
US-7264932-B2 Nuclease inhibitor cocktail APPLERA CORPORATION (US) 2007-09-04 — — US disclosed
US-20070032418-A1 Small-molecule inhibitors of angiogenin and rnases and in vivo and in vitro methods of using same AMBION, INC (US) 2007-02-08 — — US disclosed
US-20070032418-A1 Small-molecule inhibitors of angiogenin and rnases and in vivo and in vitro methods of using same AMBION, INC (US) 2007-02-08 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070032418-A1 Small-molecule inhibitors of angiogenin and rnases and in vivo and in vitro methods of using same RNASE1, RNASEH1, RNASEL CYP2C9 4801/4885CYP1A2 4375/4885THRB 3297/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback